Skip to content
    AHCO
    Earnings call· Jun 2026(Q2 FY26)

    AdaptHealth Q2 FY26 earnings call AHCO

    Aug 4, 2026 Source

    Executive summary

    AdaptHealth Q2 FY26 — Strategic Portfolio Streamlining Amidst Capitated Contract Challenges

    AdaptHealth streamlined its portfolio by divesting its Diabetes Health business and noncore Wellness-at-Home products, aiming for a focused Sleep and Respiratory core. Despite strong organic revenue growth, the company faces significant profitability challenges from its West Coast capitated contract and an unexpected manufacturer price increase, leading to a reset of its full-year outlook. Management is leveraging technology and operational efficiencies to mitigate these headwinds and improve long-term profitability.

    Highlights

    5

    • Net revenue from continuing operations grew 12.7% year-over-year to $740.3 million.

    • Organic growth from continuing operations was 15.9% year-over-year.

    • Divestiture of Diabetes Health business for $235 million, expected to improve growth and margin profile.

    • myAPP users increased 56% since the end of 2025 to 512,000, with an AI-powered mask fitting tool converting 92% of in-app scans to completed orders.

    • Secured $19 million in annualized savings from workforce restructuring.

    Concerns

    5

    • West Coast capitated contract challenges led to a $55 million guide down for FY26 adjusted EBITDA.

    • Manufacturer price increase resulted in a $30 million impact in the second half of 2026.

    • Noncash goodwill impairment of $144.2 million related to the Diabetes Health divestiture.

    • Free cash flow was negative $20.9 million for the quarter.

    • A $15 million reduction in H2 projections for other noncore wellness product exits, with ongoing servicing costs.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full-year 2026 Net Revenue (continuing operations)
    $2.85 billion to $2.89 billion
    high materiality
    High
    Full-year 2026 Adjusted EBITDA (continuing operations)
    $490 million to $520 million
    high materiality
    High
    Full-year 2026 Free Cash Flow
    $80 million to $120 million
    high materiality
    High
    Q3 2026 Net Revenue
    $720 million to $740 million
    medium materiality
    High
    Q3 2026 Adjusted EBITDA Margin
    approximately 17.9%
    medium materiality
    High
    Q3 2026 Free Cash Flow
    approximately $50 million
    medium materiality
    High
    Net Leverage Target
    2.5x
    high materiality
    High
    West Coast Capitated Contract Long-term Target Margin
    20%
    high materiality
    High
    West Coast Capitated Contract Run Rate Profitability
    reaching run rate profitability next year
    high materiality
    Medium
    Stranded Corporate Overhead Removal
    roughly half within 12 months
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Sleep Health
    Net revenue increased 15.5% versus the prior year.
    		$386.5 million15.5%——
    Respiratory Health
    Net revenue increased 14.1% versus the prior year.
    		$194.4 million14.1%——
    Wellness-at-Home
    Net revenue increased 4.9% versus the prior year.
    		$159.4 million4.9%——
    Total Capitated Revenue
    Total capitated revenue grew to $103.3 million, representing approximately 14% of continued operations net revenue, driven primarily by the West Coast capitated contract.
    Percentage of continued operations net revenue: 14%
    		$103.3 millionmore than 3x——

    Operational metrics

    16
    Organic growth (continuing operations)
    15.9%YoY
    Q2 FY26

    Organic growth for continuing operations.

    Adjusted EBITDA (continuing operations)
    $132.0 millionvs $136.4 million prior year
    Q2 FY26

    Adjusted EBITDA for continuing operations, reflecting elevated costs from the West Coast capitated contract ramp.

    Adjusted EBITDA margin (continuing operations)
    17.8%
    Q2 FY26

    Adjusted EBITDA margin for continuing operations.

    Adjusted EBITDA (discontinued operations)
    approximately $23 million
    Q2 FY26

    Adjusted EBITDA produced by discontinued operations, covering corporate overhead.

    Corporate overhead (remaining in continuing operations)
    $14 million
    Q2 FY26

    Corporate overhead expenses that remain in continuing operations after the Diabetes Health divestiture.

    West Coast capitated contract miss vs. expectations
    $15 million
    Q2 FY26

    The West Coast capitated contract missed expectations by $15 million in Q2.

    Goodwill impairment
    $144.2 million
    Q2 FY26

    Noncash goodwill impairment triggered by reallocation of shared corporate costs after Diabetes Health divestiture, impacting Respiratory Health and Wellness-at-Home.

    Capital expenditures
    $166.2 million
    Q2 FY26

    Capital expenditures to support the capitated contract, including one-time equipment and vehicle purchases.

    Workforce restructuring annualized savings
    $19 million
    Q2 FY26

    Annualized savings achieved from workforce restructuring in Q2.

    myAPP users
    512,000up 56% since end of 2025
    Q2 FY26

    Number of users on the myAPP platform, showing significant growth.

    AI-powered mask fitting tool conversion rate
    92%
    first 2 weeks

    Conversion rate for the new AI-powered mask fitting tool, indicating reduced mask refittings.

    West Coast capitated contract profitability impact
    $40 million
    H2 2026

    Expected impact on profitability relative to prior projections for the second half of the year due to West Coast capitated contract challenges.

    Manufacturer price increase impact
    $30 million
    H2 2026

    Anticipated impact in the second half of 2026 from a manufacturer's price increase.

    Other portfolio actions impact
    $15 million
    H2 2026

    Reduction in second half projections for other intentional actions to focus and strengthen the portfolio, specifically winding down certain noncore wellness products.

    Stranded corporate overhead from Diabetes Health divestiture
    $60 million
    FY26

    Corporate overhead that had previously been allocated to Diabetes Health but will remain with continuing operations.

    Delayed draw term loan triggered
    $325 million
    after Q2 FY26

    Delayed draw term loan secured as part of April refinancing, used to redeem 6.125% senior notes due 2028.

    Industry KPIs

    3
    MetricValueDetails
    Utilization trendshigher than expected
    Membership covered lives by line478,000members
    Adjusted EPS EBITDA leverage guidance3.06xx

    Deals & partnerships

    4
    Undisclosed buyerSale of Diabetes Health business$235 million

    Signed a definitive agreement to sell the Diabetes Health business.

    Leading e-commerce competitor and a telehealth prescriber networkContribution of CPAP Shop (direct-to-consumer e-commerce business)

    Signed an agreement to contribute the CPAP Shop into a newly created joint venture to reach the undiagnosed OSA population through home sleep testing and a digitally enabled path from diagnosis to treatment.

    Humana OneHomeNew capitated agreement

    Signed a new capitated agreement, successfully transitioning 478,000 new members in South Florida and Texas without disruption. This expands the capitated relationship with Humana to 33 states plus the District of Columbia and South Florida.

    Several multi-hospital health systemsPreferred provider agreements

    Secured preferred provider agreements through the newly formed enterprise sales team.

    Risks & headwinds

    5
    West Coast Capitated Contract ProfitabilityFY26, H2 2026

    $55 million guide down for FY26 adjusted EBITDA; $15 million miss in Q2; $40 million projected impact in H2 2026.

    Mitigation: Working with partner to align ordering practices, introducing technology to streamline workflows, shifting fulfillment to drop ship, rightsizing fleet and labor. Expect sequential improvement over next several quarters, reaching run rate profitability next year.

    Manufacturer Price IncreaseH2 2026

    $30 million impact in H2 2026.

    Mitigation: Actively working with the manufacturer to secure improved pricing and terms. Exploring mitigation strategies such as supplier mix adjustments and potential CPI-U impact.

    DME Moratorium on West CoastOngoing; hopeful expiration August 2024

    Limits ability to serve additional fee-for-service patients from 40 new West Coast locations, hindering absorption of fixed costs.

    Mitigation: Acting as though the moratorium extends until new PTANs (Medicare billing numbers) can be secured. Once lifted, substantial opportunity to serve patients insured through other payers and proactively sell to other customers.

    Noncore Wellness Product ExitsH2 2026 and next couple of quarters

    $15 million reduction in H2 projections. Costs of servicing existing patient census will continue.

    Mitigation: Shutting down sales channels for these products and actively working to transition existing patients to other providers over the next few quarters to reduce labor and operating expenses.

    Stranded Corporate OverheadWithin 12 months of deal close

    $60 million of corporate overhead previously allocated to Diabetes Health remains in continuing operations post-divestiture.

    Mitigation: Expect to remove roughly half of the stranded cost within 12 months. The remaining portion will be absorbed through organic growth and accretive M&A, alongside continued discipline in expense structure.

    What to watch in Q3 FY26

    5

    West Coast Capitated Contract Profitability

    Next several quarters, next year
    Current$15M miss vs. expectations in Q2, $40M projected impact in H2 2026.
    TargetSequential improvement, reaching run rate profitability next year.

    Why it matters

    Critical for overall company profitability and validation of the capitated contract strategy.

    We expect sequential improvement over the next several quarters, reaching run rate profitability next year.

    Q&A highlights

    7

    What segment is impacted by the $30 million manufacturer price increase, and what levers does AdaptHealth have to offset this impact?

    Suzanne Foster stated that due to active negotiations, the specific segment cannot be disclosed. Mitigation strategies include looking at supplier mix and product profitability, with potential future CPI-U benefits. The situation is TBD until negotiations conclude.

    “At this point, given we're in active negotiation, I prefer not to say which segment it is hitting, but I can talk about what we're doing now.”

    asked by Michael Murray · answered by Suzanne Foster

    2 min read6 chapters

    Detailed Narrative

    01

    Portfolio Streamlining and Strategic Focus

    AdaptHealth completed significant portfolio actions, including the divestiture of its Diabetes Health business for $235 million, exiting noncore Wellness-at-Home products, and contributing its e-commerce business (CPAP Shop) into a new joint venture. These moves aim to focus the company on its core Sleep, Respiratory, and supporting HME businesses, where it sees the strongest value proposition and growth path. This quarter marks the completion of a multi-year divestiture strategy to simplify the business, allowing future investments to be concentrated on core growth areas.

    02

    West Coast Capitated Contract Challenges

    The company experienced higher-than-expected order volumes, particularly in sleep resupply and enteral products, and inefficiencies in inherited workflows (e.g., nonstandard urgent orders) with its West Coast capitated contract. These issues led to elevated logistics and labor costs, impacting profitability by $55 million for FY26. Management is working with its partner to align ordering practices, introducing technology to streamline workflows, shifting more fulfillment to drop ship, and rightsizing its fleet and labor to address these challenges and improve margins.

    03

    Manufacturer Price Increase Impact

    AdaptHealth was notified on June 30th by a manufacturer of their decision to terminate its contract and impose an immediate price increase effective July 1st. This is expected to result in a $30 million impact in the second half of 2026. The company is actively negotiating for improved pricing and terms and exploring mitigation strategies such as adjusting supplier mix and leveraging future CPI-U adjustments, though the full impact is currently reflected in the outlook.

    04

    Technology and Operational Efficiency

    The company is leveraging technology to fundamentally reengineer the patient journey, exemplified by its myAPP platform. myAPP users grew 56% to 512,000 since the end of 2025, offering features like AI-powered intake, order tracking, self-scheduling, and an AI-powered mask fitting tool that converted 92% of in-app scans to completed orders in its first two weeks. This digital transformation aims to improve patient experience, accelerate cost efficiencies by removing human intermediaries, and free up staff for higher-value work.

    05

    Workforce Restructuring and Cost Savings

    In response to cost pressures, AdaptHealth made the difficult decision in Q2 to restructure its workforce, achieving $19 million in annualized savings while maintaining full operational delivery across every function. This action, alongside technology adoption and portfolio streamlining, is part of a broader effort to improve the company's cost basis and adapt to rapid growth, which has stressed its cost structure.

    06

    Capitated Growth Strategy and Humana Expansion

    AdaptHealth continues to expand its capitated relationships, signing a new agreement with Humana OneHome to transition 478,000 new members in South Florida and Texas. The company views capitated contracts as strategically valuable for gaining market density, owning a majority of patients exclusively, and reducing administrative costs through simplified billing and real-time collections, despite the current West Coast challenges. The Humana expansion represents a new geography for AdaptHealth, acquired through an RFP process.

    AI-generated summary of the company’s earnings call. Not investment advice.